| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10220917 | Ophthalmology | 2018 | 7 Pages |
Abstract
Despite having worse vision/increased CST versus those without baseline MNP, eyes with concurrent DME and baseline MNP entering RIDE/RISE experienced robust VA and anatomic improvement with ranibizumab and therefore should not be excluded from therapy.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Rahul K. MD, Dante J. MD, Shamika MD, Avanti OD, Na PhD, Carlos MD, Caroline R. MD,